News Related to Overactive Bladder

Related coverage linked through entity extraction aliases.

Zydus Settles Mirabegron Patent Dispute with Astellas for $120 Million

Feb 13, 2026

Zydus Lifesciences resolves US patent litigation with Astellas Pharma over generic Mirabegron for $120 million plus per-unit licensing fees through September 2027, enabling continued US marketing.

TrumpRx Platform Launches With Mixed Savings on Prescription Drugs

Feb 10, 2026

The Trump administration launched TrumpRx.gov in February 2026, offering discounted prices on dozens of brand-name prescription drugs through negotiated deals with pharmaceutical companies, though critics warn many listed drugs have cheaper generic alternatives.